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SUMMARY
Six patients with large uterine fibroids were given a single subcutaneous implant
ofan LHRH analogue (goserelin 3
-5 mg) prior to elective hysterectomy. Overall
fibroid volume decreased by 30-47% within six weeks of implantation. All
patients reported improvement in theirsymptoms ofpressure andpain, and were
rendered amenorrhoeic prior to surgery.
INTRODUCTION
Goserelin, a high potency luteinizing hormone - releasing hormone (LHRH)
analogue is available as a slow release subcutaneous implant (Zoladex ICI), which
has been shown to produce consistent, reversible suppression of the pituitary-
ovarian axis.1 The release offollicle stimulating hormone and luteinizing hormone
from the pituitary gland is under the control of pulsatile release of LHRH from
the hypothalmus. Continuous administration of LHRH analogues causes pituitary
gonadotrophes to become desensitised, which induces a state of hypogonado-
trophic hypogonadism, a process known as pituitary down -regulation. As a result
ofthis oestrogen output from the ovary decreases and serum oestrogen levels fall
to values in the postmenopausal range.
LHRH analogues are increasingly advocated in the management of common
oestrogen -dependent gynaecological conditions, notably uterine fibroids,2 3
endometriosis4,5 and menorrhagia,6 and mayalso be effective inthemanagement
of metastatic breast cancer.7 Recent work2,3 has shown the effectiveness of both
buserelin and goserelin in shrinking uterine fibroids to about 50% oftheir original
size (assessed by ultrasonic measurement), but both these studies showed
regrowth of the fibroids to their former size within months of stopping therapy.
Thiswork prompted Shaw to suggest that LHRH analogues should be used as an
adjunct to the surgical management of fibroids.2
The aim of the present study was to measure the effect of a single implant of
goserelin on large fibroid masses prior to elective surgery, to determine its effect
on the patients' symptoms and to record side effects.
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PATIENTS AND METHODS
Six patients, aged 42 - 50 years, parity 0 - 2, were recruited tothe studyfrom the
gynaecological clinic ofthe Ulster Hospital. All had menorrhagia, dysmenorrhoea
and generalised lower abdominal pain and pressure.
On clinical examination each patient had a firm abdominal mass equivalent in size
to a 16 - 20 week pregnancy. Clinically these were fibroid masses and ultrasound
examination supported this diagnosis. The patients were offered abdominal total
hysterectomy and bilateral salpingo -oophorectomy with postoperative hormone
replacement therapy as the treatment of choice. Each was given an admission
date within 4 - 8 weeks.
After informed consent forthe present study wasobtained, each patient received
a 3 -5 mg goserelin implant into the anterior abdominal wall after local infiltration
with 1 % lignocaine. They were then reviewed weekly for ultrasonic assessment of
the maximum length (a), depth (b) and width (c) ofthetumour. Measurements (a)
and (b) were taken in the longitudinal plane and (c) in the transverse plane. Ultra-
sound scanning wasperformed on an Ultramark 4 machineby oneobserver. After
obtaining a picture of what was regarded as the maximum size of the mass, the
ultrasonographer freeze-framed the picture and turned the screen away. The
second observer performed the measurements and obtained hardprint copies of
these. Fibroid volume was determined by the formula of an ellipsoid according to
Shawker's method.8 Weeklymeasurementsofserum FSH, LH and 1713 -oestradiol
values were obtained, symptoms were reviewed and any side effects noted.
Following operation the fibroid volume was measured immediately by fluid
displacement in a measuring jug.
RESULTS
Overall fibroid volume estimated by ultrasound showed a 30-46% reduction
in the study period (Table 1), the shrinkage being obvious within two weeks in
all cases and maximum by four weeks (Fig 1). This reduction was evident on
palpation. The shrinkage coincided with the postmenopausal levels of oestradiol
( < 50 pmol/l) achieved with the treatment. These levels were reached in all
cases by four weeks from implantation (Fig 2). These coincided with hypo-
gonadotrophic levels of FSH and LH (< 2 IU/I).
TABLE I
Ultrasonic estimates of original and immediate preoperative fibroid volume and
percentage reduction in size
Original Preoperative
fibroid fibroid
Patient volume (ml) volume (ml) Shrinkage
OA 1033 557 46%
JC 951 581 39%
ED 815 453 44%
MM 660 353 46%
FS 600 420 30%
JH 542 350 33%
© The Ulster Medical Society, 1992.
52Shrinkage of uterine fibroids 53
GOSERELIN AND FIBROID MASS OA
Jc
1200 LiJ
" 1000-
E 1300-
600- w t-
1 400 --
200
0 2 4 6 8
Week Number Since Implant
Fig 1. Ultrasonic estimate of fibroid volume in
the weeks following goserelin implant up to the
day before surgery.
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Fig 2. Serum oestrogen levels after goserelin
implantation.
The estimated volume by scan prior to surgery corresponded to within 5 - 14%
of the actual volume of the surgical specimen (minus ovaries and tubes) as
determined by fluid displacement (Table 11). The ultrasound volumes were all
under-estimated.
TABLE II
Comparison of ultrasonic estimation of immediate preoperative fibroid volume
and actual volume ofsurgical specimen measured by fluid displacement
Preoperative
estimated Actual
fibroid fibroid
Patient volume (ml) volume (ml) Discrepancy
OA 558 636 -14%
JC 581 648 -11%
ED 453 475 -5%
MM 353 385 -9%
FS 420 441 -5%
JH 350 388 -10%
All patients reported improvement in their symptoms of pain and pressure,
evident between the second and third week of treatment. One patients had slight
vaginal staining during the treatment, but menstruation was delayed in all patients
prior to hysterectomy. One patient was just commencing menstruation at the
time of hysterectomy, 61 days after her implant. The only side effects noted were
hot flushes (four patients) which coincided with the low oestradiol levels.
Despite shrinkage of the fibroid mass in all patients, a debulking procedure
(myomectomy) was required in two patients in order to gain access to the uterine
pedicles. Postoperatively the only complication was one self-limiting episode of
paralytic ileus. Histopathology confirmed the diagnosis in all cases: in two endo-
metriosis was found in the ovaries.
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DISCUSSION
We report major shrinkage of large uterine fibroids following a single subcutan -
eous implant of goserelin. Some studies have suggested that medical manage-
ment offibroids with a LHRH analogueis analternative tosurgery9" 0 butothers2'3
have shown complete regrowth of fibroids within months of cessation of this
therapy. The long-term use of LHRH analogue with subsequent hypooestrogen-
ism has not been studied but this therapy does induce a premature menopause
with the associated problems of climacteric symptoms and, in the long-term,
potential atherosclerotic and osteoporotic changes. We would agree with Shaw2
who suggested that the LHRH analogue should be used as an adjunct to surgical
management. The implant could be repeated at four-weekly intervals if surgery
was delayed. Surgery also allows full histological assessment with a firm diagnosis
and rules out malignancy.
Important aspects of this combined chemosurgical approach include full patient
compliance and acceptability, improvement in symptoms and absence of serious
side effects. Goserelin is expensive (f;114 per implant) but this must be weighed
against other positive factors and potential savings. The cessation of menses over
the treatment period should allow anaemia to be corrected by simple haematinics
and might save the need for blood transfusion in some patients with severe
menorrhagia.6 Surgery could also be made easier in several ways. Matta et al
have shown by Doppler blood flow studies that the blood supply to fibroids and
the uterus is decreased after a LHRH analogue." In our series, a debulking
procedure (myomectomy) still had to be performed in two cases but blood loss
was not a problem. Access to the uterine pedicles should be easier when fibroids
are smaller and thesurgical incision might be modified from a longitudinal midline
incision to a transverse lower abdominal incision.
One important factor in the selection of patients is to exclude the possibility of
an ovarian tumour. Fibroids have a characteristic ultrasonic appearance and
shrinkage is obvious both clinically and ultrasonically within three weeks. It is
unlikely, therefore, that a misdiagnosis would be made, but with this chemo-
surgical approach, surgery would be performed within a few months and the time
factor involved would make little difference in prognosis.
The fibroids appeared to demarcate prior to shrinkage and one huge mass
appeared to separate into the various fibroids making up the mass. It has been
shown that fibroids have increased cytoplasmic oestrogen receptors compared to
adjacent myometrium'2 but our impression on serial scanning was that the
myometrium shrank around the fibroid first, which allowed the fibroids to
demarcate.
Concern has been expresed regarding the potential side effects of the LHRH
agonists. The only side effects recorded by our patients were tolerable hot flushes
and these were offset by relief of pain and pressure. In theory, long-term usage of
a LHRH analogue could be associated with bone loss or coronary artery disease.
Our patients did not show any change in serum calcium or alkaline phosphatase
during the short period ofthis study. Van Leusden and Dogterom did notfind any
bone loss following six months of continuous treatment with a LHRH analogue.'3
We contend that this chemosurgical approach to large fibroids is safe, effective
and beneficial to the patient. One implant produces significant benefits and this
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schedule could be incorporated into standard clinical practice. Close follow-up of
patients preoperatively seems unnecessary as there are few side effects.
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